Johnson & Johnson's immunology stalwart Stelara went head-to-head against AbbVie's megablockbuster Humira in Crohn's disease, looking for bragging rights to help it compete in that market. It didn't ...
SYDNEY--(BUSINESS WIRE)--NeuClone Pharmaceuticals Ltd (NeuClone) today announced its biosimilar candidate of Stelara ® (ustekinumab), NeuLara, has successfully met all primary and secondary endpoints ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback